Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Good
|
New words:
adversarial, AG, aggressive, alter, anniversary, annuity, antagonist, antibody, array, assert, assignee, assumed, backup, billion, Biopharma, biosimilar, block, blocking, breadth, broad, brownian, cancellation, Carlo, certainty, cessation, checkpoint, circumvented, CMO, commonplace, conceived, conclusion, concurrent, concurrently, conferred, configured, consecutive, contrast, correct, counsel, crowded, cumulative, Curetech, curtail, cycle, declaratory, degree, desirable, desired, Display, dispute, distraction, documentary, dominant, downstream, dual, earliest, effort, envision, exacerbate, exceeding, familiarity, family, fee, flexibility, forma, found, Franc, freedom, functional, geometric, Germany, GITR, halt, hampered, hand, headcount, herpetic, identification, ii, iii, illustrative, impinge, implied, impractical, inadvertent, inadvertently, IND, indirectly, intangible, inter, introduce, inventor, inventorship, ipilimumab, IV, January, jeopardize, lag, landscape, lapse, lead, leading, leave, lesion, lifetime, literature, Ludwig, maintenance, managerial, Medimmune, misappropriate, missed, mix, modulator, molecular, monoclonal, monospecific, Monte, motion, narrowed, narrower, noncompliance, opposition, optimization, optimize, organized, pro, procedural, proceed, ramp, rapid, reactive, readout, Recepta, reexamination, reinstated, relief, remind, retired, Retrocyte, rightfully, SA, SEC, secret, sequence, shelf, shift, simulation, site, sought, Squibb, stable, suitable, supplemental, Switzerland, synergy, tangible, Tesaro, threat, throughput, treasury, trending, underwritten, unenforceable, unissued, unlikelihood, viability, vulnerability, yearly, Yervoy
Removed:
America, AOCI, BLA, brain, build, California, Canada, center, CEO, clarify, cognizant, consulting, consume, contemplated, contracted, creditable, dated, decision, detail, diminished, duration, enforced, enjoined, entirety, equivalent, ESPP, Europe, European, expectation, exploit, exploring, Francisco, free, generating, governed, HSP, identical, importing, instituted, invent, long, nonrefundable, offset, partially, passage, post, progression, proliferation, proposed, provoked, reclassification, reclassified, reference, reflected, reform, refuse, Restated, reviewing, San, screening, select, send, Separately, September, sizable, source, stopping, subcontract, subsequently, suggesting, survival, tested, thereon, thereunder, unclear, underway, untested, untried, upheld, violated, virtually, yielded
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 Collaborative Research and Development Agreement
- 10.2 Collaborative Research and Development Agreement
- 10.3 Sublease Agreement
- 10.3.1 Amendment to Sublease
- 10.3.2 Amendment 4 to Sublease
- 10.3.3 Amendment 5 to Sublease
- 10.3.4 Amendment 6 to Sublease
- 10.4 Commercial Lease Agreement
- 10.4.1 Amendment 20 to Commercial Lease
- 10.4.2 Amendment 28 to Commercial Lease
- 10.4.3 Amendment 29 to Commercial Lease
- 31.1 Certificate of CEO Pursuant to Section 302
- 31.2 Certificate of Pfo Pursuant to Section 302
- 32.1 Certificate of CEO and Pfo Pursuant to Section 906
- Download Excel data file
- View Excel data file
Related press release
AGEN similar filings
Filing view
External links
Addendum No. 6 to the Lease Agreement from 01/28/2011 between
4-Antibody AG, Hochbergerstr. 60C, 4057 Basel
(Sublessee)
and
Technologie Park Basel AG, Hochbergerstr. 60C, 4057 Basel
(Principal Lessee)
The two parties named above declare that the following spaces are removed from the leased spaces in Technologie Park Basel (Hochbergerstrasse 60C, 4057 Basel) as of 07/31/2013:
- Office: C4_33, 4th Floor, approx. 12 m2, rent costs:
per month | per year | |
Rent | CHF 300.00 | CHF 3,600.00 |
Incidental costs | CHF 68.75 | CHF 825.00 |
VAT (8%) | CHF 29.50 | CHF 354.00 |
Total | CHF 398.25 | CHF 4,779.00 |
4-Antibody AG | Technologie Park Basel AG |
Basel, on [hw:] __________ | Basel, on [hw:] 06/24/2013 |
[signature] Dr. Robert Burns Chief Executive Officer | [signature] Samuel Hess VR1 |
[signature] Melanie Princip Group Head of HR | [signature] Nina Ryser VR2 |